The Joint Committee on Vaccination and Immunisation (JCVI) — the expert body that advises the UK government on vaccine policy — has recommended that teenagers be offered a meningitis B (MenB) vaccine on the NHS. The move reverses the committee's position from just four months earlier and follows a series of outbreaks that killed teenagers in early 2026. The Guardian

The advisory body, chaired by Prof Wei Shen Lim, set out a multi-part programme on 16 July 2026. For children who received a MenB jab as a baby — those born on or after 1 May 2015 — the JCVI recommended a booster dose around age 15. The first group under that recommendation will turn 15 in 2030. Children who missed the infant MenB jab would receive two doses, given at least 28 days apart. The committee also called for a catch-up programme so that anyone who misses a vaccine does not lose out.

The recommendation still requires government approval, and each UK nation would decide on funding and delivery independently.

This is a notable shift. As of 18 March 2026, the JCVI had not recommended a routine MenB booster for adolescents and young adults, according to the UK Health Security Agency. UKHSA The intervening months brought developments that clearly changed that thinking. The most serious outbreak hit Kent earlier in 2026 and left two teenagers dead. Among them was Juliette Kenny, 18, whose family then campaigned for teenagers to routinely get access to the MenB vaccine.

The Kent outbreak spread far beyond public health guidance. In March 2026, pharmacies across the UK reported shortages of the MenB vaccine as demand surged, and the UK government released 20,000 NHS vaccine doses to the private market to fill the supply gap. Reuters

The JCVI's routine adolescent recommendation is separate from a one-off programme announced earlier in 2026. That programme offers the MenB vaccine to Year 13 pupils and to under-25 students starting university or residential education, with first doses available from 20 July 2026. UKHSA The routine recommendation, by contrast, is designed as an ongoing immunisation schedule rather than a time-limited response.

Data behind the JCVI's decision suggests the MenB vaccine provides strong protection for at least five years after vaccination. That durability makes a teenage booster viable for children who received the infant dose, since immunity can fade during adolescence — a period of higher risk for meningococcal disease — and a booster given at 15 would address that before university entry, when transmission risk rises in shared living settings.

The broader context here is one of policy shifting under public pressure. The JCVI's March 2026 non-recommendation sat alongside an active outbreak and grieving families calling for broader access. By July, the committee had moved to a recommendation covering routine adolescent vaccination, a catch-up programme, and a booster schedule. Whether the four UK health departments move quickly enough to fund and deliver the programme before the next academic year's university intake remains an open question, and one that the one-off summer programme was designed to bridge in the interim.

The separation between the one-off programme and the routine recommendation also carries implementation risk. Families and providers will need clear communication about who is eligible to avoid confusion between a time-limited offer starting 20 July and a future routine schedule that, for the booster component, will not begin in earnest until 2030. The catch-up programme's scope and timeline will be critical for teenagers currently in the gap — too old for the infant programme, too young for the university-targeted one-off, and facing a multi-year wait before routine adolescent delivery reaches their age group.